Interest of thalidomide in cutaneo-mucous and hypothalamo-hypophyseal in langerhans cell histiocytosis;Intérêt du thalidomide au cours des localisations cutanéomuqueuses et hypothalamohypophysaires de l'histiocytose langerhansienne

Revue de Medecine Interne

Volumn 23, Issue 7, 2002, Pages 651-656

  Claudon, A ^a   Dietemann, J L ^b   Hamman De Compte, A ^a   Hassler, P ^a  

^a Centre Hospitalier de Haguenau   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Histiocytosis X; Langerhans cell histiocytosis; Thalidomide

Indexed keywords

THALIDOMIDE;

ADULT; ARTICLE; CANCER INFILTRATION; CASE REPORT; CELL PROLIFERATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENITAL TRACT TUMOR; HISTIOCYTOSIS X; HUMAN; HYPOPHYSIS TUMOR; HYPOTHALAMUS TUMOR; MOUTH TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTE; SKIN TUMOR;

EID: 0036314348     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(02)00627-6     Document Type: Article

References (15)

1. Histiocytosis syndrome in children
2. Histiocytose langerhansienne de l'adulte: Localisations cutanéomuqueuses régressives après traitement par thalidomide
3. Histiocytoses
4. Histiocytose X avec «granulome éosinophile vulvaire»: Effet spectaculaire du thalidomide
5. Histiocytose langerhansienne de l'adulte: Localisation parotidienne régressive après traitement par thalidomide
6. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide
7. Pure cutaneous histiocytosis resembling sinus histiocytosis
8. Remission of Langerhans cell histiocytosis with thalidomide treatment
9. Adult cutaneous Langerhans cell histiocytosis: Remission with thalidomide treatment
10. Hypothesis: Thalidomide embryopathy-proposed mechanism of action
11. Rediscovering thalidomide: A review of its mecanism of action, side effects, and potential uses
12. Thalidomide decreases the production of GM-CSF and TNFα in the mixed epidermal cell-lymphocyte reaction
13. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
14. Antitumor activity of thalidomide in refractory multiple myeloma
15. Phase II evaluation of thalidomide in patients with metastatic breast cancer